Eukaryotic expression vectors and immunoconjugates for cancer therapy

E. M. Glinka, E. F. Edelweiss, S. M. Deyev

Research output: Contribution to journalReview articlepeer-review

4 Citations (Scopus)


This review considers ways to address specificity to therapeutic targeted anticancer agents. These include transcriptional activation of tissue-and tumor-specific promoters in eukaryotic expression vectors and use of antitumor-lirected immunoconjugates. The review deals with analysis of strategies used for selection of targeted promoters and examples of antibody fusion proteins exhibiting antitumor activity. A new direction in antitumor treatment pooling together methods of gene therapy and antibody therapy has appeared. This direction is based on the development of vectors encoding secreted forms of immunoconjugates. After vector introduction into a cell, the latter is capable of synthesizing and secreting antibody fusion protein composed of a therapeutic anticancer agent and antibody specifically targeted to cancer cells.

Original languageEnglish
Pages (from-to)597-606
Number of pages10
JournalBiochemistry (Moscow)
Issue number6
Publication statusPublished - Jun 2006
Externally publishedYes


  • Anticancer agent
  • Fusion protein
  • Gene therapy
  • Immunoconjugate
  • Secreted protein

ASJC Scopus subject areas

  • Biochemistry

Fingerprint Dive into the research topics of 'Eukaryotic expression vectors and immunoconjugates for cancer therapy'. Together they form a unique fingerprint.

Cite this